Intravenous Immunoglobulin (Ivig) has 5 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Pozelimab, Eculizumab, Eculizumab-Aeeb. Patients taking Intravenous Immunoglobulin (Ivig) should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 5
- Major
- 1
- Moderate
- 3
Major (1)
- Intravenous Immunoglobulin (Ivig) + Pozelimab— Intravenous immunoglobulin may decrease pozelimab concentrations by interfering with FcRn recycling mechanism. Avoid con…
Moderate (3)
- Intravenous Immunoglobulin (Ivig) + Eculizumab— In patients with gMG on concomitant IVIg treatment, concomitant use can reduce serum eculizumab concentrations and requi…
- Intravenous Immunoglobulin (Ivig) + Eculizumab-Aeeb— In patients with gMG, concomitant use can reduce serum eculizumab concentrations and requires supplemental dosing.
- Intravenous Immunoglobulin (Ivig) + Ravulizumab— Concomitant use can reduce serum ravulizumab concentrations and requires a supplemental dose of ULTOMIRIS.